# Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

> **NCT07532148** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 24 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** CKD-215
- **DRUG:** D215

## Key facts

- **NCT ID:** NCT07532148
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2027-06
- **Final completion:** 2027-08
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07532148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07532148, "Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07532148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*